The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: A study in 686 consecutive patients

American Heart Journal

Volumn 152, Issue 4, 2006, Pages 736-741

  de Groote, Pascal ^a   Lamblin, Nicolas ^a,b   Helbecque, Nicole ^b   Mouquet, Frédéric ^a   Hermant, Xavier ^b   Amouyel, Philippe ^b   Dallongeville, Jean ^b   Bauters, Christophe ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

ADENOSINE MONOPHOSPHATE DEAMINASE 1 GENE; ADULT; ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY EXERCISE TEST; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA ANALYSIS; DNA POLYMORPHISM; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FOLLOW UP; GENE; GENETIC ANALYSIS; HEART LEFT VENTRICLE CONTRACTION; HETEROZYGOTE; HOMOZYGOTE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SCINTIANGIOGRAPHY; SURVIVAL RATE;

EID: 33748679351     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.04.003     Document Type: Article

References (24)

1. Morisaki T., Sabina R.L., and Holmes E.W. Adenylate deaminase. A multigene family in humans and rats. J Biol Chem 265 (1990) 11482-11486
2. Fishbein W.N., Armbrustmacher V.W., and Griffin J.L. Myoadenylate deaminase deficiency: a new disease of muscle. Science 200 (1978) 545-548
3. Morisaki T., Gross M., Morisaki H., et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A 89 (1992) 6457-6461
4. Norman B., Glenmark B., and Jansson E. Muscle AMP deaminase deficiency in 2% of a healthy population. Muscle Nerve 18 (1995) 239-241
5. Norman B., Mahnke-Zizelman D.K., Vallis A., and Sabina R.L. Genetic and other determinants of AMP deaminase activity in healthy adult skeletal muscle. J Appl Physiol 85 (1998) 1273-1278
6. Tarnopolsky M.A., Parise G., Gibala M.J., et al. Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J Physiol 533 (2001) 881-889
7. Kalsi K.K., Yuen A.H., Rybakowska I.M., et al. Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation-a potential mechanism of protection in heart failure. Cardiovasc Res 59 (2003) 678-684
8. Norman B., Sabina R.L., and Jansson E. Regulation of skeletal muscle ATP catabolism by AMPD1 genotype during sprint exercise in asymptomatic subjects. J Appl Physiol 91 (2001) 258-264
9. Loh E., Rebbeck T.R., Mahoney P.D., et al. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 99 (1999) 1422-1425
10. Anderson J.L., Habashi J., Carlquist J.F., et al. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 36 (2000) 1248-1252
11. Gastmann A., Sigusch H.H., Henke A., et al. Role of adenosine monophosphate deaminase-1 gene polymorphism in patients with congestive heart failure (influence on tumor necrosis factor-alpha level and outcome). Am J Cardiol 93 (2004) 1260-1264
12. Yazaki Y., Muhlestein J.B., Carlquist J.F., et al. A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. J Card Fail 10 (2004) 316-320
13. de Groote P., Millaire A., Foucher-Hossein C., et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. J Am Coll Cardiol 32 (1998) 948-954
14. de Groote P., Dagorn J., Soudan B., et al. B type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 43 (2004) 1584-1589
15. Hansen J.E., Sue D.Y., and Wasserman K. Predicted values for clinical exercise testing. Am Rev Respir Dis 129 (1984) S49-S55
16. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
17. Andreassi M.G., Botto N., Laghi Pasini F., et al. AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization. Int J Cardiol 101 (2005) 191-195
18. Kolek M.J., Carlquist J.F., Thaneemit Chen S., et al. The role of a common adenosine monophosphate deaminase (AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure. J Card Fail 11 (2005) 677-683
19. Rico Sanz J., Rankinen T., Joanisse D.R., et al. Associations between cardiorespiratory responses to exercise and the C34T AMPD1 gene polymorphism in the HERITAGE Family Study. Physiol Genomics 14 (2003) 161-166
20. Kelemen J., Rice D.R., Bradley W.G., et al. Familial myoadenylate deaminase deficiency and exertional myalgia. Neurology 32 (1982) 857-863
21. Sinkeler S.P., Joosten E.M., Wevers R.A., et al. Myoadenylate deaminase deficiency: a clinical, genetic, and biochemical study in nine families. Muscle Nerve 11 (1988) 312-317
22. Rubio J.C., Martin M.A., Rabadan M., et al. Frequency of the C34T mutation of the AMPD1 gene in world class endurance athletes: does this mutation impair performance?. J Appl Physiol 98 (2005) 2108-2112
23. Rossi A., Cicoira M., Zanolla L., et al. Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. J Am Coll Cardiol 40 (2002) 1425-1430
24. Isnard R., Pousset F., Chafirovskaia O., et al. Combination of B type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. Am Heart J 146 (2003) 729-735